Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of ...

Celgene's European leader Tuomo Pätsi talks to pharmaphorum about the firm's remarkable growth, which is set to continue thanks to myeloma blockbuster Revlimid and new psoriasis and psoriatic ...

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...